ZEN 3365

Drug Profile

ZEN 3365

Alternative Names: ZEN 003365; ZEN3365

Latest Information Update: 23 Sep 2014

Price : $50

At a glance

  • Originator Zenith Epigenetics Corp
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Lymphoproliferative disorders; Solid tumours

Most Recent Events

  • 23 Sep 2014 Preclinical trials in Solid tumours in Canada (PO)
  • 23 Sep 2014 Preclinical trials in Lymphoproliferative disorders in Canada (PO)
  • 23 Sep 2014 Preclinical trials in Acute myeloid leukaemia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top